Back to Browse Journals » Biosimilars

Biosimilars ceased publishing in October 2016. All new submissions can be made to Biologics: Targets and Therapy. All articles that have been published in Biosimilars will continue to be available on the Dove Press site, and will be securely archived with CLOCKSS.

Biosimilars


Journal Articles:

- 31 records -

Physicochemical and biological comparison of the first Brazilian biosimilar filgrastim with its reference product

Mantovani M, Caruso CS, Facchini FDA, Pascon R, Cagnacci PRV, de Magalhães VD

Biosimilars 2016, 6:45-60

Published Date: 30 August 2016

Adalimumab: a review of the reference product and biosimilars

Azevedo VF, Troiano LDC, Galli NB, Kleinfelder A, Catolino NM, Martins PCU

Biosimilars 2016, 6:29-44

Published Date: 26 July 2016

Tools for the analysis and characterization of therapeutic protein species

Fuh MM, Steffen P, Schlüter H

Biosimilars 2016, 6:17-24

Published Date: 5 May 2016

Considerations in biosimilar insulin device development

Fry AR, Krentz AJ, Hompesch M

Biosimilars 2016, 6:9-15

Published Date: 16 February 2016

Development, safety, and efficacy of biosimilar adalimumab: the data so far

Gabbani T, Deiana S, Bagnoli S, Annese V

Biosimilars 2016, 6:1-7

Published Date: 29 January 2016

Label-free interaction analysis as a tool to demonstrate biosimilarity of therapeutic monoclonal antibodies

Sinha-Datta U, Khan S, Wadgaonkar D

Biosimilars 2015, 5:83-91

Published Date: 16 September 2015

Low immunogenicity but reduced bioavailability of an interferon beta-1a biosimilar compared with its biological parent: results of MATRIX, a cross-sectional, multicenter phase 4 study

Cuevas C, Deisenhammer F, You X, Scolnik M, Buffels R, Sperling B, Flores-Ramírez F, Macías-Islas M, Sauri-Suárez S

Biosimilars 2015, 5:75-81

Published Date: 15 September 2015

Clinical efficacy and safety of biosimilar epoetin: focus on epoetin zeta

Mikhail A, Brown C

Biosimilars 2015, 5:65-73

Published Date: 9 September 2015

Clinical trials in the development of biosimilars: future considerations

Huneycutt BJ, Gillespie E, Woollett GR

Biosimilars 2015, 5:49-63

Published Date: 9 July 2015

Establishing a new marketplace for biologic therapy with biosimilar agents: importance of extrapolation of data

Bressler B, Dingermann T

Biosimilars 2015, 5:41-48

Published Date: 1 June 2015

Challenging issues in assessing analytical similarity in biosimilar studies

Chow SC

Biosimilars 2015, 5:33-39

Published Date: 22 May 2015

Global regulatory landscape of biosimilars: emerging and established market perspectives

Krishnan A, Mody R, Malhotra H

Biosimilars 2015, 5:19-32

Published Date: 17 February 2015

Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197

Bandyopadhyay S, Mahajan M, Mehta T, Singh AK, Parikh A, Gupta AK, Kalita P, Patel M, Mendiratta SK

Biosimilars 2015, 5:1-18

Published Date: 31 December 2014

Production and manufacturing of biosimilar insulins: implications for patients, physicians, and health care systems

Kuhlmann MK, Schmidt A

Biosimilars 2014, 4:45-58

Published Date: 10 November 2014

Production and analysis of a biosimilar erythropoietin in Egypt

Ebied WM, Ahmed HM, Elbarbry FA

Biosimilars 2014, 4:11-22

Published Date: 10 May 2014

Clinical efficacy and safety of Zarzio® (EP2006), a biosimilar recombinant human granulocyte colony-stimulating factor

Tharmarajah S, Mohammed A, Bagalagel A, MacDonald K, Abraham I

Biosimilars 2014, 4:1-9

Published Date: 12 March 2014

Clinical efficacy and safety of Tevagrastim® (XM02), a biosimilar recombinant human granulocyte colony-stimulating factor

Bagalagel A, Mohammed A, MacDonald K, Abraham I

Biosimilars 2013, 3:55-62

Published Date: 27 August 2013

Clinical efficacy and safety of XM01, a biosimilar recombinant human erythropoietin, in the management of anemia

Mohammed A, Bagalagel A, MacDonald K, Abraham I

Biosimilars 2013, 3:45-53

Published Date: 27 August 2013

Clinical efficacy and safety of SB309, a biosimilar recombinant human erythropoietin, in the management of anemia

Bagalagel A, Mohammed A, MacDonald K, Abraham I

Biosimilars 2013, 3:35-43

Published Date: 21 August 2013

Current and future biosimilars: potential practical applications in rheumatology

Noaiseh G, Moreland L

Biosimilars 2013, 3:27-33

Published Date: 1 August 2013

Rituximab and biosimilars – equivalence and reciprocity

Qureshi ZP, Magwood JS, Singh S, Bennett CL

Biosimilars 2013, 3:19-25

Published Date: 14 June 2013

Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases

Desanvicente-Celis Z, Caro-Moreno J, Enciso-Zuluaga M, Anaya JM

Biosimilars 2013, 3:1-17

Published Date: 4 January 2013

A European perspective on the market accessibility of biosimilars

Declerck PJ, Simoens S

Biosimilars 2012, 2:33-40

Published Date: 16 November 2012

The development and introduction of biosimilar anticoagulants – focus on enoxaparin

Ginsberg JS

Biosimilars 2012, 2:27-31

Published Date: 13 September 2012

Clinical efficacy and safety of HX575, a biosimilar recombinant human erythropoietin, in the management of anemia

Abraham I, MacDonald K

Biosimilars 2012, 2:13-25

Published Date: 6 September 2012

Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics

Chow SC, Endrenyi L, Lachenbruch PA, Yang LY, Chi E

Biosimilars 2011, 1:13-26

Published Date: 16 June 2011

Biosimilars: an overview

Bhupinder Singh Sekhon, Vikrant Saluja

Biosimilars 2011, 1:1-11

Published Date: 15 March 2011